Brutally underpriced stock with MASSIVE upside Potential here...

Brutally underpriced stock with MASSIVE upside Potential here ... Lots of MEGA milestones are imminent like the Phase 2 readout of the NASH trial a potential multi Blockbuster drug which is partnered with pharma giant Boehringer Ingelheim , another MEGA milestone which is imminent is the potential Partner Deal for the LOXL2 Program which means HUGE Upfront payments to Pharmaxis . This is the most attractive pharma gem in down under this one has everything to be the next Disallowed but its more likely that the company getting bought before reaching their full potential .GL guys


Pharmaxis (PXS.AX)

Market-Cap:AU$ $75 Million
Cash: AU$ 29.2 M
Price: 0.19


Presentation
https://www.asx.com.au/asxpdf/20190726/pdf/446xcj608spgpw.pdf


Shareholder Update
https://www.asx.com.au/asxpdf/20191031/pdf/44b334qcbyb7g5.pdf


Boehringer snaps up Pharmaxis liver disease drug
https://www.prnewswire.com/news-releases/boehringer-ingelheim-acquires-pharmaxis-phase-1-anti-inflammatory-drug-candidate-300084609.html

Boehringer Ingelheim has exercised an option to acquire Pharmaxis’ PXS4728A to develop it for the treatment of a type of liver disease called NASH, in a move potentially worth more than $A750 million (around $600 million).